Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469203 | 0.87 | BCHE (0.41) | POLBDPP4GAABCHEATM | |
| SCHEMBL6471113 | 0.85 | TMEM97 (0.44) | POLBDPP4KDM4EGAANAMPT | |
| SCHEMBL6468178 | 0.84 | DPP4 (0.47) | POLBDPP4CHEK1MAOBSMN1; SMN2 | |
| SCHEMBL6471056 | 0.82 | NOS1 (0.46) | MAOBBCHEL3MBTL1 | |
| SCHEMBL6470737 | 0.77 | EGFR (0.43) | MAOBBCHEKCNH2TMEM97 | |
| SCHEMBL5131617 | 0.76 | BCHE (0.58) | GAASMN1; SMN2BCHEATML3MBTL1 | |
| SCHEMBL5133519 | 0.76 | CPB2 (0.40) | KDM4ESMN1; SMN2BCHEKCNH2 | |
| SCHEMBL6469030 | 0.75 | KCNH2 (0.56) | POLBDPP4GAABCHEATM | |
| SCHEMBL5042778 | 0.75 | TMEM97 (0.63) | GAABCHEATMKCNH2TMEM97 | |
| SCHEMBL5132093 | 0.74 | ADRB2 (0.41) | SMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | POLB 2718/4885DPP4 3527/4885KDM4E 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.